capitalize on each organization’s unique capabilities with the goal of discovering breakthrough medicines for patients across numerous illness categories. King’s has one of the world’s strongest portfolios of scientific discovery and will offer biological research discoveries that have the potential to lead to the development of high-impact medications.
Additionally, the affiliated hospitals and clinician scientists of the university are well-positioned to provide clinical development assistance for initiatives. The translational scientists and drug development architects of Apollo will advance these research initiatives through clinical testing and eventually to patients using Apollo’s asset-centric portfolio strategy.
Professor Reza Razavi, Vice President (Research) at King’s College London, expressed delight over the partnership. He said, “Translating our biomedical research into effective therapies that improve health is a key priority for King’s researchers. I am delighted that this new partnership with Apollo will provide new routes for us to achieve this goal”. He added, “Apollo has an excellent track record in partnering with academics to progress their discoveries into therapies. King’s researchers are looking forward to working with Apollo to progress promising therapeutic programs into their drug discovery pipeline and on to clinical impact.”
Dr. Richard Mason, chief executive officer of Apollo, expressed optimism over the collaboration. He said, “When looking at research output, King’s College London is one of the largest and most successful centers for biomedical research and education in the UK and indeed globally. With its broad clinical presence, we have also found King’s has exceptional insight in selecting and advancing research that can translate effectively into therapeutic programs”. He added, “We are proud to initiate this partnership with our newest collaborator as we look to grow both our portfolio of programs and our relationships with the world’s leading scientists and biomedical institutions. This collaboration continues to build on the recent progress we have made in advancing our internal pipeline, building our team and establishing our US operations in Cambridge, Mass.”
